Navigation Links
Interleukin Genetics to Chair Expert Panel Discussion on Use of Biomarkers in Drug Development at BIO Convention
Date:5/12/2009

Senior Experts from Nordic Bioscience, Biomarker Strategies and Pharma on Panel

WALTHAM, Mass., May 12 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that CEO Lewis H. Bender will moderate and co-present a panel discussion titled "Integrating Genetic Markers in Drug Development: How Personalized Medicine is Evolving Predictive Treatment" at the BIO International Convention, being held May 18-21, 2009 in Atlanta, GA. The panel discussion will be held Tuesday, May 19 from 8-9:30 a.m. in Room B304 of the Georgia World Congress Center (Building B).

Co-presenting alongside Interleukin Genetics will be Reid Leonard, Ph.D., Executive Director of Licensing and External Research, Merck Research Laboratories; Douglas Clark, M.D., Chief Scientific Officer, Biomarker Strategies; and Morten Karsdal, Ph.D., Vice President, Research and Development, Nordic Bioscience.

"Biomarkers can be effectively used to improve the success rate in drug development. Genetic biomarkers that can be used to screen and select for patients in clinical trials to improve likelihood of trial success and improve safety for patients can save costs and reduce the time needed to bring new compounds to market," said Mr. Bender. "We're pleased that the Biotechnology Industry Organization recognizes the importance of this topic by selecting this panel to present."

The panel will provide expert insights, respectively, on integration and commercialization issues for biomarkers in drug development and how simple genetic tests and other types of biomarkers are poised to help curb an increasing innovation gap especially with regard to complex diseases. Discussion will focus on:

  • The various different biomarker types that can be used effectively for drug development

    • '/>"/>

SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Interleukin Genetics Announces Conference Call to Discuss First Quarter 2009 Results
2. Interleukin Genetics Grants LABEC Pharma a License for Sales and Distribution of Its Heart Health Genetic Test
3. Interleukin Genetics Receives NYSE Amex Staff Determination, Requests Oral Hearing Before the Listing Qualifications Panel
4. Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
5. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
6. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
7. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
8. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
9. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
10. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. Interleukin-12 indicates survival prospects for melanoma patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ty of Michigan determined that only 663,000 of the...s C virus (HCV) infection received antiviral thera...to be declining, in part because only half of the ...ng trend continues, by 2030 less than 15% of liver...viral therapy. This study, the first to analyze n...
(Date:11/23/2009),, NEWYORK,Nov.23/PRNewswire/--Livingwithchronicpaincanbedifficult-andthestressoftheholidayseasoncanprovetobequitechallengingforthoselivingwithpain. ,, ListentothisreportfromPfizerInc.at: ,
(Date:11/23/2009)...ok for the high cost of drug advertising that does...ed by a University of British Columbia health poli...the Archives of Internal Medicine , examined the ...ug also known by the trade name Plavix used to pre... drug was selected to study the impact of advertis...
(Date:11/23/2009)... suffering from women,s hair loss for almost ten y...he,s sharing her progress and the secret behind he...e release of her video diaries which include a dir...reatment. , (PRWeb UK) No...Zsanett Siklosi has released the video diaries tha...
(Date:11/23/2009)...n might ease the problem, researchers say , ...bottle up their anger over unfair treatment at wor...dy indicates. , Men who consistently failed to ...low worker or supervisor were more than twice as l...se as those who vented their anger, claims a repor...
Breaking Medicine News(10 mins):Health News:Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US 2Health News:Drug ads ineffective for boosting sales, could cost taxpayers: UBC-Harvard study 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 2Health News:Stifled Anger at Work Doubles Men's Risk for Heart Attack 3
...opene, other nutrients no shield against prostate ...14 (HealthDay News) -- Men who,ve been adding vita...ts to cut their risk of prostate cancer may need t...odds of prostate malignancy -- findings that are i...
...T LAKE CITY, Sept. 14 Dynatronics,Corporation (Na...th quarter,and fiscal year ended June 30, 2007. Ne...943 ($.02 per share), compared to $39,101 ($.00 pe...r the year ended June 30, 2007 were $17,837,104, c...
...NDALE, Mich., Sept. 14 Nearly 300 of,Detroit,s mo...f art to be,auctioned at the twelfth annual "ART W...5:00 p.m. on Sunday, September 23, 2007 at The Rit...tioneer Jim Miller, hors d,oeuvres, a cash bar, va...
...ANN ARBOR, Mich.---Using atom-level imaging techni...aled important structural details of an enzyme sys...ole in helping the body efficiently break down man...es. , The system involves two proteins that work ...
...Many sets of guidelines and regulations, and great...l researchers encounter if they want to use previo...arch. For one thing, this makes it extremely comp... (CBE), together with leading biobank researchers,...
...g-Term Outlook More Favorable as Drugs from Eli Li... 2016, According to a New Report ...pt. 12 Decision Resources, one of the,world,s lea...Astellas,s Flomax/Harnal, combined with the limite...
Other Medicine News:Health News:Tomato Diet Can't Guarantee Prostate Health: Study 2Health News:Tomato Diet Can't Guarantee Prostate Health: Study 3Health News:Tomato Diet Can't Guarantee Prostate Health: Study 4Health News:Dynatronics Announces Strong Fourth Quarter Profit 2Health News:Dynatronics Announces Strong Fourth Quarter Profit 3Health News:Revealing the workings of 'Mother Nature's blowtorch' 2Health News:Long-awaited international ethical guidelines for biobank researchers 2Health News:Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs 2
(Date:11/23/2009)...wswire-FirstCall/-- LexiconPharmaceuticals,Inc. (N...sPhase2clinicalstudywith LX1031 inpatientswithnon-...ntedatGASTRO2009inLondonthisweek.Resultsfromthestu...,willbepresentedbyDr. PhilipM.Brown ,Lexicon,sseni...2009at2:30pmlocaltimeatthesessionentitled,"Therape...
(Date:11/23/2009)...ire-FirstCall/--WoundManagementTechnologies,Inc.,(...cialtymedicalproducts,announcedthatithasfileditQ32...agementbusinessupdatetoillustratethedevelopmentsdu...ed33.5%to$102,926vs.Q32008salesof$77,084. , S...vs.Q32008shareholderequityof$(321,257) , Tota...
(Date:11/23/2009)...3/PRNewswire-FirstCall/--Anesiva,Inc.(Nasdaq: ANSV...chardhaveagreedtojointheAnesivaboardofdirectorsfol...ndArcionTherapeutics.Completionofthemergerissubjec...uslyannouncedAnesiva2009AnnualMeetingofStockholder...Point,Suite107A,SouthSanFrancisco,California,among...
Breaking Medicine Technology:Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 54336 1OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 54336 2OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma 54336 3Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 54332 1Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 54332 2Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 54332 3Pennsylvania Patient Safety Authority Marks Milestone With One Million Reports 54332 4Perfect Fitness Ranks No 1 of Consumer Product Companies on 2009 Inc 500 List Ranks No 4 Overall 54327 1Perfect Fitness Ranks No 1 of Consumer Product Companies on 2009 Inc 500 List Ranks No 4 Overall 54327 2
...w Subset Analyses To Be Presented --, SAN FRANCISC...tion, Inc. today announced that data from the Comp...heimer,s disease will be,presented for the first t...f Neurology,s 59th Annual Meeting in Boston on Thu...ntation will include new,data from both the mild a...
...R--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharm...ive results from its,post-clearance marketing stud...ivate(R) cream, a mid-strength topical steroid in ...tis (AD)., The study, which took place at five cen... patients receiving treatment with,Cutivate(R) and...
Other Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 2Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 3Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 4Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 5Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints 6
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
...UP Laboratories is a national reference laboratory...esearch and development. ARUP offers an extensive ...ts in clinical and anatomic pathology. Owned by th...nclude more than half of the nation's university t...
Medicine Products: